Jiangsu Lianhuan Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Jiangsu Lianhuan Pharmaceutical has been growing earnings at an average annual rate of 13.4%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 14.2% per year. Jiangsu Lianhuan Pharmaceutical's return on equity is 9.9%, and it has net margins of 6.1%.
Key information
13.4%
Earnings growth rate
13.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 14.2% |
| Return on equity | 9.9% |
| Net Margin | 6.1% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses Breakdown
How Jiangsu Lianhuan Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,251 | 136 | 744 | 140 |
| 31 Dec 23 | 2,174 | 135 | 714 | 132 |
| 30 Sep 23 | 2,026 | 131 | 722 | 103 |
| 30 Jun 23 | 2,013 | 137 | 739 | 97 |
| 31 Mar 23 | 2,002 | 142 | 737 | 95 |
| 31 Dec 22 | 1,955 | 141 | 729 | 92 |
| 30 Sep 22 | 1,888 | 132 | 710 | 86 |
| 30 Jun 22 | 1,783 | 130 | 676 | 71 |
| 31 Mar 22 | 1,718 | 124 | 664 | 67 |
| 31 Dec 21 | 1,646 | 119 | 644 | 66 |
| 30 Sep 21 | 1,591 | 109 | 602 | 52 |
| 30 Jun 21 | 1,529 | 112 | 610 | 49 |
| 31 Mar 21 | 1,426 | 109 | 561 | 47 |
| 31 Dec 20 | 1,386 | 103 | 535 | 44 |
| 30 Sep 20 | 1,366 | 97 | 527 | 52 |
| 30 Jun 20 | 1,352 | 83 | 528 | 51 |
| 31 Mar 20 | 1,337 | 82 | 576 | 48 |
| 31 Dec 19 | 1,290 | 80 | 609 | 47 |
| 30 Sep 19 | 1,183 | 79 | 621 | 43 |
| 30 Jun 19 | 1,110 | 76 | 622 | 42 |
| 31 Mar 19 | 1,040 | 74 | 586 | 39 |
| 31 Dec 18 | 1,019 | 74 | 564 | 38 |
| 30 Sep 18 | 936 | 77 | 514 | 21 |
| 30 Jun 18 | 857 | 74 | 452 | 32 |
| 31 Mar 18 | 782 | 73 | 410 | 22 |
| 31 Dec 17 | 689 | 71 | 362 | 20 |
| 30 Sep 17 | 614 | 67 | 304 | 20 |
| 30 Jun 17 | 590 | 69 | 291 | 0 |
| 31 Mar 17 | 580 | 63 | 276 | 0 |
| 31 Dec 16 | 605 | 63 | 275 | 0 |
| 30 Sep 16 | 615 | 58 | 288 | 0 |
| 30 Jun 16 | 625 | 56 | 288 | 0 |
| 31 Mar 16 | 628 | 51 | 294 | 0 |
| 31 Dec 15 | 642 | 50 | 300 | 0 |
| 30 Sep 15 | 652 | 48 | 298 | 0 |
| 30 Jun 15 | 661 | 46 | 297 | 0 |
| 31 Mar 15 | 673 | 45 | 289 | 0 |
| 31 Dec 14 | 669 | 44 | 283 | 0 |
| 30 Sep 14 | 672 | 44 | 265 | 0 |
| 30 Jun 14 | 673 | 42 | 257 | 0 |
| 31 Mar 14 | 647 | 41 | 244 | 0 |
| 31 Dec 13 | 623 | 38 | 234 | 0 |
| 30 Sep 13 | 592 | 37 | 219 | 0 |
| 30 Jun 13 | 578 | 37 | 214 | 0 |
Quality Earnings: 600513 has high quality earnings.
Growing Profit Margin: 600513's current net profit margins (6.1%) are lower than last year (7.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600513's earnings have grown by 13.4% per year over the past 5 years.
Accelerating Growth: 600513's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 600513 had negative earnings growth (-4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).
Return on Equity
High ROE: 600513's Return on Equity (9.9%) is considered low.